Deal Library / Pharma BD Deal Intelligence

Gilead Sciences, Inc. — Pharma Deals

The Pharma Closeout tracks 5 deals, $4.4B in disclosed deal value, 4 with a post-close Outcome Score for Gilead Sciences, Inc..

Median Critic Score: 64 · Median Outcome Score: 20

All 5 deals

Gilead Sciences, Inc. / Calistoga Pharmaceuticals, Inc. — 2011 · $600M · Underwhelmed — fell short of the thesis.
Gilead Sciences, Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) — 2016 · $1.2B · Did not work — the deal failed to deliver.
Gilead Sciences, Inc. / Galapagos NV — 2016 · $2.1B · Did not work — the deal failed to deliver.
Gilead Sciences, Inc. / YM BioSciences Inc. — 2012 · $510M · Did not work — the deal failed to deliver.
Gilead Sciences, Inc. / Tibotec Pharmaceuticals (Janssen) — 2011